AKTA avant 25: Top-Tier CDMO’s Downstream Purification Strategy
The biopharmaceutical manufacturing market, particularly the CDMO (Contract Development and Manufacturing Organization) industry, is currently undergoing a massive paradigm shift. As the market’s gravity shifts from traditional monoclonal antibodies (mAb) focused on mass production to highly complex next-generation modalities such as Antibody-Drug Conjugates (ADCs), utilizing advanced platforms like the AKTA avant 25 has become a … Read more